HPS Pharmacies wish to give notice that Pfizer are anticipating a supply interruption for gentamicin ampoules as follows:
Pfizer Gentamicin Injection BP
Gentamicin (as sulfate) 80mg/2mL
Normal supplies are expected to resume by end January 2020. An internationally registered brand of gentamicin (as sulfate) 80mg/2mL has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
This alternative product is a suitable option in most situations. However, this product contains the preservatives methylparaben and propylparaben which may cause irritation to the airways if used as an inhalation. The Therapeutic Goods Administration (TGA) advises healthcare professionals who would have used Pfizer Gentamicin injection ampoules via inhalation to consider other therapies or request supply of a preservative-free gentamicin product via the Special Access Scheme (SAS).
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates